☆ 4.6 Review

Adjuvant immunotherapy in renal cell carcinoma: a systematic review and meta-analysis

BJU INTERNATIONAL (2023)

Related references

Note: Only part of the references are listed.

Review Urology & Nephrology

Risk models for recurrence and survival after kidney cancer: a systematic review

Juliet A. Usher-Smith et al.

Summary: This study systematically compared the performance of different prognostic models in predicting survival or recurrence in patients with localized renal cell cancer who underwent surgery. The study found that several models had good discriminative ability, and there was no single "best" model. When choosing a model, both the comparative performance and the availability of factors included in the model should be considered.

BJU INTERNATIONAL (2022)

Add to Collection

Article Urology & Nephrology

2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma

Jens Bedke et al.

Summary: Adjuvant pembrolizumab, an immune checkpoint inhibitor, showed significant improvement in disease-free survival (DFS) for high-risk clear cell renal cell carcinoma patients. However, the overall survival (OS) data are not yet available.

EUROPEAN UROLOGY (2022)

Add to Collection

Review Urology & Nephrology

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update

Borje Ljungberg et al.

Summary: The European Association of Urology has prepared evidence-based guidelines for the management of RCC, which were updated in 2022 using a standardized methodology. The guidelines provide transparent and reliable evidence for the management of RCC, based on a thorough literature assessment and clinical practice recommendations.

EUROPEAN UROLOGY (2022)

Add to Collection

Article Oncology

EVEREST: Everolimus for renal cancer ensuing surgical therapy—A phase III study (SWOG S0931, NCT01120249).

Christopher W. Ryan et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline

W. Kimryn Rathmell et al.

Summary: The article provides recommendations for the management of patients with metastatic clear cell renal cell carcinoma (ccRCC), including diagnosis, treatment, and participation in clinical trials.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Adjuvant nivolumab plus ipilimumab (NIVO plus IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial

R. J. Motzer et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial

Sumanta Kumar Pal et al.

Summary: The objective of this study was to determine if adjuvant atezolizumab delayed recurrence in renal cell carcinoma patients with an increased risk of recurrence. The study found that adjuvant atezolizumab did not improve clinical outcomes in patients with renal cell carcinoma.

LANCET (2022)

Add to Collection

Article Oncology

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles et al.

LANCET ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial

M. Allaf et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials

Lorenzo Marconi et al.

Summary: This study utilized a European database to provide estimated survival time benchmarks for high-risk RCC patients receiving immunotherapy after nephrectomy, which can aid in patient selection and future trial design optimization.

CLINICAL GENITOURINARY CANCER (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Multidisciplinary Sciences

Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma

Ziad Bakouny et al.

Summary: Sarcomatoid and rhabdoid renal cell carcinomas are highly aggressive tumors that exhibit high responsiveness to immune checkpoint inhibitors. Molecular characterization in this study revealed specific alterations and an immune-inflamed phenotype in these tumors.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Medicine, General & Internal

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Matthew J. Page et al.

SYSTEMATIC REVIEWS (2021)

Add to Collection

Article Medicine, General & Internal

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

T. K. Choueiri et al.

Summary: The study showed that adjuvant pembrolizumab therapy significantly improved disease-free survival compared to placebo among high-risk kidney cancer patients after surgery, with a positive impact on overall survival as well.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Oncology

Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis

Ekaterina Laukhtina et al.

Summary: Our analysis found that adjuvant TKI therapy in patients with localized and locally advanced RCC significantly improved disease-free survival (DFS) compared to placebo, but did not result in a significant overall survival (OS) benefit. Additionally, TKI therapy was associated with significant toxicity, suggesting that it may not offer a satisfactory risk and/or benefit balance for all patients.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2021)

Add to Collection

Article Medicine, General & Internal

Evaluation of Oncology Trial Results Reporting Over a 10-Year Period

Xu Liu et al.

Summary: This study analyzed the reporting of results among interventional oncology trials registered on ClinicalTrials.gov from 2007 to 2017, finding a gradual improvement in results reporting over the ten-year period. Factors associated with results reporting rate included trial date, sample size, and funding source.

JAMA NETWORK OPEN (2021)

Add to Collection

Article Immunology

Complement as Prognostic Biomarker and Potential Therapeutic Target in Renal Cell Carcinoma

Britney Reese et al.

JOURNAL OF IMMUNOLOGY (2020)

Add to Collection

Review Oncology

Adjuvant therapy in renal cell carcinoma

Anita Gul et al.

CANCER (2019)

Add to Collection

Article Medicine, General & Internal

RoB 2: a revised tool for assessing risk of bias in randomised trials

Jonathan A. C. Sterne et al.

BMJ-BRITISH MEDICAL JOURNAL (2019)

Add to Collection

Article Urology & Nephrology

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results

Robert J. Motzer et al.

EUROPEAN UROLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

A. Ravaud et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Oncology

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation

Richard W. Joseph et al.

CANCER IMMUNOLOGY RESEARCH (2015)

Add to Collection

Article Multidisciplinary Sciences

Positive Outcomes Influence the Rate and Time to Publication, but Not the Impact Factor of Publications of Clinical Trial Results

Pilar Sune et al.

PLOS ONE (2013)

Add to Collection

Article Urology & Nephrology

Monitoring of Plasma Cell-Free DNA in Predicting Postoperative Recurrence of Clear Cell Renal Cell Carcinoma

JingJing Wan et al.

UROLOGIA INTERNATIONALIS (2013)

Add to Collection

Article Oncology

Serum cell-free DNA in renal cell carcinoma

Michela de Martino et al.

CANCER (2012)

Add to Collection

Article Urology & Nephrology

Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system

JS Lam et al.

JOURNAL OF UROLOGY (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.